SBRT Dose for Solitary Mediastinal Lymph Node (1.2 cm)
For a 1.2 cm solitary mediastinal lymph node, I recommend 35 Gy in 5 fractions (7 Gy per fraction), which represents the most commonly used and well-validated SBRT regimen for oligometastatic mediastinal lymph nodes with excellent local control and acceptable toxicity.
Rationale and Evidence Base
The 2026 ASTRO dose-volume histogram consensus guidelines 1 provide critical organ-at-risk constraints for ultrahypofractionated 5-fraction lung SBRT regimens (10-12 Gy per fraction to 50-60 Gy total). While these guidelines focus on primary lung cancer, they establish the safety framework for mediastinal SBRT delivery.
The most robust clinical evidence comes from recent multi-institutional studies specifically addressing mediastinal lymph node oligometastases:
A 2025 multicentre retrospective study 2 of 63 mediastinal lymph node metastases treated with SBRT reported median dose of 30 Gy in 5 fractions, achieving 1-year and 2-year local control rates of 96.9% and 91.8% respectively, with only one late grade 3 toxicity.
A 2023 single-center CyberKnife series 3 demonstrated that 36 Gy in 6 fractions (66% of their cohort) had significantly lower local progression rates compared to other fractionation schemes, with 6,12, and 18-month local control of 94%, 88%, and 72%.
A 2021 large academic center series 4 of 84 mediastinal/hilar metastases used median dose of 35 Gy in 5 fractions (range 30-50 Gy), achieving 2-year local failure rate of only 9.0%, though with 11.5% grade ≥3 toxicity (mostly transient).
Dose Selection Algorithm
For your 1.2 cm mediastinal lymph node, consider this approach:
Standard recommendation: 35 Gy in 5 fractions (BED10 = 59.5 Gy)
Alternative if proximity to critical structures: 36 Gy in 6 fractions (6 Gy per fraction)
- Superior local control demonstrated 3
- Lower dose per fraction may reduce toxicity risk
- BED10 = 61.2 Gy (similar biological effect)
Dose escalation consideration: 40-50 Gy in 5 fractions
Critical Organ-at-Risk Constraints (5-Fraction Regimen)
When planning 35 Gy in 5 fractions, you must respect these constraints 1:
- Esophagus: D0.035cc ≤38 Gy (primary goal); D5cc ≤19.5 Gy
- Heart: D0.035cc ≤38 Gy; D15cc ≤32 Gy
- Trachea/Main Bronchus: D0.035cc ≤40 Gy; D0.5cc ≤21 Gy
- Spinal Canal: D0.035cc ≤32 Gy (for 5-fraction regimen)
- Great Vessels: D0.035cc ≤105% of prescription dose
- Brachial Plexus: D0.035cc ≤32 Gy
Technical Planning Considerations
Modern techniques are mandatory 6, 2:
- Use IMRT or VMAT (not conventional 3D-conformal)
- Define GTV based on PET-CT imaging (gold standard for nodal metastases) 7
- CTV = GTV + 0.5-1.0 cm margin (respecting anatomic boundaries) 6
- PTV accounts for setup uncertainty and motion
- Consider 4D-CT for motion assessment 8
Common pitfall: The mediastinum contains multiple dose-limiting serial organs. If you cannot meet all OAR constraints with 35 Gy in 5 fractions, do not compromise the constraints—instead, either:
- Switch to 36 Gy in 6 fractions (lower dose per fraction)
- Consider moderately hypofractionated regimen (e.g., 45-50 Gy in 10 fractions)
- Use conventional fractionation if SBRT is not feasible
Expected Outcomes
With appropriate dosing (30-36 Gy in 5-6 fractions):
- Local control: 88-97% at 1-2 years 2, 3, 4
- Median time to new systemic therapy: 12-17 months 2, 3
- Grade ≥3 toxicity: 0-11.5% (mostly transient) 2, 3, 4
- Overall survival: 75-86% at 2 years 2, 4
The evidence strongly supports that SBRT for oligometastatic mediastinal lymph nodes delays systemic therapy progression and provides excellent local control with acceptable toxicity when delivered with appropriate dose constraints.